无锡帕母医疗技术有限公司
{{company.company_channel.channel_name}}
Media Room
{{company.company_name_local}}
{{company.company_channel.channel_name}}
Company Profile
Media Room
Pulnovo Medical Announces PADN Receives FDA HUD Designation and US CMS Medicare Coverage Code and NMPA Approval 2024-01-02 20:30
Pulnovo Medical Announces 3-Year Follow-up Results from PADN-5 at THT 2023, The Medical Device Maker Breaks New Ground in Heart Failure Treatment 2023-03-28 20:30
Pulnovo Medical Reports Positive One-year Results for PADN-CFDA Trial in Pulmonary Arterial Hypertension (PAH) Treatment 2023-02-28 10:19
Pulnovo Medical Announces Dr. Mingdong Zhang, Former FDA Medical Device Officer Joins Scientific Advisory Board 2023-01-14 22:00
Pulnovo Medical Announces Dr. Mingdong Zhang, Former FDA Medical Device Officer Joins Scientific Advisory Board 2023-01-04 10:46
Pulnovo Medical will be attending JPM Healthcare Conference 2023 2022-12-24 20:00
Pulnovo Medical Inhales Tens of Millions Dollars Funding to Accelerate Global Growth 2022-11-07 20:30
TCT2022| Pulnovo Medical Announced That The Latest Results Of PADN-CFDA Pivotal Trial Indicate Effectiveness And Safety of PADN For The Treatment Of Pulmonary Arterial Hypertension (PAH) 2022-09-23 20:30
Pulnovo Medical Released Results From PADN-CFDA Pivotal Trial For The Treatment Of Pulmonary Arterial Hypertension (PAH) 2022-09-20 20:30
Pulnovo Medical Concludes Successfully the First Steering Committee Meeting 2022-09-08 20:30
Pulnovo Medical Limited's PADN Technology Included in 2022 ESC/ERS Guidelines for the Diagnosis and Treatment of PH 2022-09-07 20:30
Pulnovo Medical Concludes Successfully First Pre-Sub Meeting with FDA for PADN Global Clinical Trial 2022-07-15 20:30
Pulnovo Medical Announces Dr. Krishna Sudhir Joins Scientific Advisory Board 2022-06-15 10:00
SCAI & CBS Pulmonary Hypertension Masterclass 2022: Based on Global Perspectives Focusing on New Breakthroughs 2022-05-24 08:30
Pulnovo Medical Appoints Ms. Jessie Lian Jia as New CEO 2022-03-10 20:00
Pulnovo Medical Announced Results From PADN-CFDA Pivotal Trial For The Treatment Of Pulmonary Arterial Hypertension (PAH) Meet The Efficacy Primary Endpoint 2022-01-01 20:30
1